文章：

HER2癌基因作为子宫浆液性癌和子宫癌肉瘤的分子靶点

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma

原文发布日期：14 August 2023

DOI: 10.3390/cancers15164085

类型: Article

开放获取: 是

英文摘要：

Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are two rare histologic variants of uterine carcinoma, with distinct molecular profiles and aggressive metastatic potential. As the effectivity of traditional platinum-based chemotherapy for USC and UCS is low, and there are high rates of resistance and recurrence, the development of novel targeted therapeutics is needed. Human epidermal growth factor receptor 2 (HER2) has proven to be an oncogene of increasing interest in these cancers, as HER2 protein overexpression and/or c-ERBB2gene amplification ranges from ~30 to 35% in USC, and between ~15 and 20% in UCS. This review summarizes the existing clinical and preclinical evidence, as well as ongoing clinical trials of HER2-targeting therapeutics, and identifies potential areas of further development and inquiry.

摘要翻译： 

子宫浆液性癌（USC）与子宫癌肉瘤（UCS）是子宫癌中两种罕见的组织学亚型，具有独特的分子特征和较强的侵袭转移潜能。由于传统铂类化疗对USC和UCS疗效有限，且耐药及复发率高，亟需开发新型靶向疗法。人类表皮生长因子受体2（HER2）已被证实是这些癌症中日益受到关注的致癌基因，在USC中HER2蛋白过表达和/或c-ERBB2基因扩增率约为30%-35%，在UCS中约为15%-20%。本综述系统总结了HER2靶向疗法现有的临床与临床前证据及正在进行的临床试验，并指出了未来值得深入探索的研究方向。

原文链接：

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma